Abbott India Ltd - Rich Valuations
However, this was partially offset by Mixtard and Novomix, which recorded 4% and -1.1% YoY growth, thereby lowering topline growth to some extent.
525 Views
Abbott India Ltd - Key Therapies Report Robust Sales Improvement
AIL reported revenue growth of 7.1% YoY in Q1FY23 (vs. our expectations of 8% YoY), outpacing the IPM* growth of 2.0% (IPM: Indian Pharma Industry,...
359 Views
Pick of the Week: Abbott India Ltd
Revenue growth of Abbott India Ltd (AIL) for FY21 has outpaced the Indian Pharma Market (IPM) growth by 100 bps majorily contributed by addition of...
326 Views
Abbott India: Key Therapies Report Robust Sales Improvement
AIL reported revenue growth of 15.9% in Q2FY22, outpacing the IPM (Indian Pharma Industry, Source: AIOCD) growth of 14.6%.
279 Views
Abbott India: Sustainable Performance Gaining Market Share
We expect Revenue/PAT CAGR of 11.1%/11.3% respectively over FY21-FY24E. While a TP of Rs 20,000 implies a marginal downside of 2.5%, we remain...
463 Views